{"id":480235,"date":"2020-04-20T11:44:02","date_gmt":"2020-04-20T11:44:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=480235"},"modified":"2020-04-20T11:44:02","modified_gmt":"2020-04-20T11:44:02","slug":"myasthenia-gravis-key-companies-involved-and-emerging-therapies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/myasthenia-gravis-key-companies-involved-and-emerging-therapies_480235.html","title":{"rendered":"Myasthenia Gravis: Key companies involved and Emerging Therapies"},"content":{"rendered":"
\"Myasthenia<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
“Myasthenia Gravis Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Myasthenia Gravis market. A detailed picture of the Myasthenia Gravis pipeline landscape is provided, which includes the disease overview and Myasthenia Gravis treatment guidelines. <\/div>\n

“Myasthenia Gravis Pipeline Insight, 2020<\/a>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Myasthenia Gravis market. A detailed picture of the Myasthenia Gravis pipeline landscape is provided, which includes the disease overview and Myasthenia Gravis treatment guidelines.<\/p>\n

The assessment part of the report embraces in-depth Myasthenia Gravis commercial assessment and clinical assessment of the Myasthenia Gravis pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myasthenia Gravis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

Download full report: <\/strong>https:\/\/www.delveinsight.com\/sample-request\/myasthenia-gravis-pipeline-insight<\/p>\n

\"\"<\/strong><\/p>\n

Scope of the report:
<\/strong>1. The Myasthenia Gravis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products<\/em> by development stage, product type, route of administration, molecule type, and MOA type for <\/em>Myasthenia Gravis across the complete product development cycle, including all clinical and nonclinical stages.
2. It comprises of detailed profiles of <\/em>Myasthenia Gravis therapeutic products<\/em> with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
3. Detailed Myasthenia Gravis research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.
4. Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across Myasthenia Gravis.<\/p>\n

Report highlights:
<\/strong>1. A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Myasthenia Gravis.  2. In the coming years, the Myasthenia Gravis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
3. The companies and academics that are working to assess challenges and seek opportunities that could influence Myasthenia Gravis R&D. The therapies under development are focused on novel approaches to treat\/improve the disease condition.
4. A detailed portfolio of major pharma players who are involved in fueling the Myasthenia Gravis treatment market. Several potential therapies for Myasthenia Gravis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Myasthenia Gravis market size in the coming years. 
5. Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Myasthenia Gravis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. <\/p>\n

The launch of the emerging therapies is expected to significantly impact Myasthenia Gravis treatment scenario in the upcoming years:-<\/strong>
Drugs covered<\/strong>
1. Rozanolixizumab<\/span>
2. CFZ533<\/span>
3. Efgartigimod<\/span>
4. RA101495<\/span>
5. IGIV-C<\/span>
6. Firdapse<\/span>
7. Hizentra<\/span>
And many others<\/span><\/p>\n

The key players in Myasthenia Gravis market are:<\/strong>
1. UCB Pharma<\/span>
2. Novartis<\/span>
3. Argenx<\/span>
4. Ra Pharmaceuticals<\/span>
5. Grifols Therapeutics<\/span>
6. Catalyst Pharmaceuticals<\/span>
7. CSL Behring<\/span>
8. And many others<\/span><\/p>\n

Request for sample pages:<\/strong> https:\/\/www.delveinsight.com\/sample-request\/myasthenia-gravis-pipeline-insight<\/span><\/p>\n

Table of contents:<\/strong><\/span><\/p>\n

1. Key Insights
2. Myasthenia Gravis Market Overview at a Glance
3. Myasthenia Gravis Disease Overview
4. Myasthenia Gravis Epidemiology and Patient Population
5. Country Wise Myasthenia Gravis Epidemiology
5.1. United States
5.2. Germany
5.3. France
5.4. Italy
5.5. Spain
5.6. United Kingdom
5.7. Japan
6. Myasthenia Gravis Current Treatment Practices
7. Unmet Needs
8. Myasthenia Gravis Marketed drugs
8.1. Key cross competition- Marketed drugs
8.2. Mestinon: Valeant Pharmaceuticals
8.3. Soliris: Alexion Pharmaceuticals
8.4. Prograf: Astellas Pharma
8.5. Venoglobulin IH: Mitsubishi Tanabe Pharma
9. Myasthenia Gravis Emerging Therapies
9.1. Key cross competition- Emerging Therapies
9.2. Rozanolixizumab: UCB Pharma
9.3. CFZ533: Novartis
9.4. Efgartigimod : Argenx
9.5. RA101495: Ra Pharmaceuticals
9.6. Firdapse: Catalyst Pharmaceuticals
9.7. Hizentra: CSL Behring
9.8. IGIV-C: Grifols Therapeutics
10. Myasthenia Gravis 7 Major Market Analysis
11. Market Outlook by Country
11.1. The United States: Market Outlook
11.2. United States Market Size
11.3. EU-5 Countries: Market Outlook
11.4. Germany
11.5. France
11.6. Italy
11.7. Spain
11.8. United Kingdom
11.9. Japan: Market Outlook
12. Market Drivers
13. Market Barriers
14. Appendix
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight<\/p>\n

About DelveInsight:<\/span>
<\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP “Myasthenia Gravis Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Myasthenia Gravis market. A detailed picture of the Myasthenia Gravis pipeline landscape is provided, which … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-480235","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/480235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=480235"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/480235\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=480235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=480235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=480235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}